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Aberrant production of nitric oxide (NO) by inducible NO synthase (iNOS) has been implicated in the
pathogenesis of endothelial dysfunction and vascular disease. Mechanisms responsible for the ﬁne-
tuning of iNOS activity in inﬂammation are still not fully understood. Zinc is an important structural
element of NOS enzymes and is known to inhibit its catalytical activity. In this study we aimed to
investigate the effects of zinc on iNOS activity and expression in endothelial cells. We found that zinc
down-regulated the expression of iNOS (mRNAþprotein) and decreased cytokine-mediated activation of
the iNOS promoter. Zinc-mediated regulation of iNOS expression was due to inhibition of NF-κB
transactivation activity, as determined by a decrease in both NF-κB-driven luciferase reporter activity
and expression of NF-κB target genes, including cyclooxygenase 2 and IL-1β. However, zinc did not affect
NF-κB translocation into the nucleus, as assessed by Western blot analysis of nuclear and cytoplasmic
fractions. Taken together our results demonstrate that zinc limits iNOS-derived high output NO
production in endothelial cells by inhibiting NF-κB-dependent iNOS expression, pointing to a role of
zinc as a regulator of iNOS activity in inﬂammation.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Endothelial dysfunction is characterized by a loss of endothelial
control over vascular tone, thrombosis, and vessel wall remodeling
[1]. Hallmarks of endothelial dysfunction is a decreased bioavail-
ability of nitric oxide (NO) and increased inﬂammation [1]. In
endothelial cells NO can be produced from L-arginine in a reaction
catalyzed by the constitutive type 3 isoform of NO synthase or
endothelial NOS (eNOS or NOS3; EC 1.14.13.39) [2]. Under pro-
inﬂammatory conditions endothelial cells express also the induci-
ble isoform of NOS (iNOS or NOS2) [2,3]. Although both NOS
isoforms catalyze the same biochemical reaction, eNOS and iNOS
are very different enzymes. The expression of eNOS is constitutive
in endothelial cells, and produces low nanomolar levels of NO. The
biochemical activity of eNOS is tightly regulated by its intracellular
localization and by post-translational mechanisms, including Ca2þ
signaling, and phosphorylation. Instead, iNOS is not expressedB.V. This is an open access article u
h Laboratory, Department of
ulty, Heinrich-Heine-Univer-
25, Germany
e (M.M. Cortese-Krott).under resting non-inﬂammatory conditions in endothelial cells,
but after its induction by pro-inﬂammatory stimuli iNOS produces
low micromolar amounts of NO independently on Ca2þ ﬂuctua-
tion until it is degraded by proteolytic enzymes [4]. iNOS is known
to exert important regulatory and protective effects on the
vasculature [2–4]. However, aberrant iNOS-derived NO production
has been shown to be involved in pathological conditions, e.g. the
blood pressure fall in septic shock [5], as well as in the pathogen-
esis of chronic inﬂammatory diseases, including atherosclerosis
[6,7]. Although in recent years both post-translational and post-
transcriptional mechanisms regulating iNOS activity have been
discovered [4,8], the regulation of iNOS expression remains the
main regulatory step to control iNOS activity [4,5].
Accumulating evidence indicates that iNOS-derived NO is also
involved in zinc homeostasis [9–11]. It has been hypothesized that
zinc released by high output NO synthesis may induce endothelial
resistance against oxidative stimuli and disease [12–14], as re-
cently reviewed [15]. It was shown that both NO donors and iNOS-
derived NO induce intracellular zinc release from zinc sulfur
clusters, as found in proteins such as metallothionein [9,11–
14,16–21]. We and others have demonstrated that iNOS-derived
NO controls zinc trafﬁcking in endothelial cells [14,16,18,20,22]nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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zinc-mediated increase of cellular glutathione de novo synthesis
[12]. Interestingly, the same pathway was activated also by
exogenously added zinc [13].
Some evidence of a possible regulatory role of zinc on iNOS
activity exists. Zinc is an important structural element of iNOS,
holding together the two subunits via tetrahedral coordination of
four cysteines, two belonging to one monomer and the other two
to the second protein monomer [23]. Thus, zinc displacement form
the zinc–sulfur cluster of iNOS by NO can contribute to the control
of iNOS activity [24]. Moreover, it is well known that transition
metals, including copper and zinc, profoundly affect NOS enzyme
activity at different levels. Stuehr and Grifﬁth have reported in a
review that in vitro iNOS activity in activated macrophages is more
than 90% inhibited by 100 mM zinc [26]. In keratinocytes zinc
supplementation was shown to decrease iNOS protein levels [27],
but the molecular mechanisms responsible of zinc-mediated iNOS
regulation were not further investigated.
In this study we analyzed the effects of zinc on iNOS activity in
aortic endothelial cells. We could demonstrate that zinc limits
high output NO production in endothelial cells by inhibiting NF-
κB-dependent expression of iNOS. Therefore, zinc might partici-
pate to control iNOS signaling and contribute to the stabilization of
the endothelium in inﬂammation by limiting NF-κB-mediated
responses.Materials and methods
Chemicals
Non-fat dry milk was purchased from BioRad (Munich, Ger-
many), materials for western blot (NuPAGE LDS sample buffer,
NuPAGE reducing agent, NuPAGE 10% Bis-Tris pre-cast gels) from
Invitrogen GmbH (Karlsruhe, Germany), Ponceaus S from SERVA
Electrophoresis GmbH (Heidelberg, Germany), Hybond P transfer
membrane from Amersham Biosciences (Munich, Germany),
mouse monoclonal anti-human β-actin, horseradish peroxidase
(HRP)-conjugated goat anti-mouse antiserum and HRP-conjugated
goat anti-rabbit antiserum from BD biosciences (Erembodegem,
Belgium), pro-inﬂammatory cytokines (PeproTech INC, Rocky Hill,
USA), and L-N5-(1-iminoethyl)-ornithine-dihydrochloride (L-NIO)
from Alexis Biochemicals (Lörrach, Germany). Unless otherwise
speciﬁed, chemicals were purchased from Sigma (Deisenhofen,
Germany), cell culture plastics from Greiner (Frickenhausen, Ger-
many) and cell culture material from PAA (Pashing, Austria).Isolation and culture of rat aorta endothelial cells
Rat aorta endothelial cells were isolated by outgrowth from
aortic rings, expressed the phenotype vWFhigh Ox43high eNOShigh
and were cultured as described [13,28].Culture of A549/8 iNOS cells
The human alveolar epithelium-like A549/8 cells stably trans-
fected with a 16 kB fragment of the human iNOS promoter in front
of a luciferase reporter gene and a neomycin resistance gene was a
kind gift of Prof. Dr. H. Kleinert (Institute of Pharmacology,
Johannes Gutenberg-University of Mainz) [29]. Cells were grown
in RPMI 1640/10% FCS supplemented with 1 mg/ml Geneticin
G418. Experiments were performed in the absence of G418.Zinc determination
The zinc concentrations of cell culture media, sera and buffers
were determined by ﬂame atomic adsorption spectrometry as
described previously [13]. We found that FBS contained
24.9872.00 mM zinc and the complete medium 2.2870.32 mM
zinc. Increase in intracellular “free” zinc concentration after addi-
tion of zinc to culture media was measured by loading with
Zinquin as described [13].
Measurement of iNOS derived NO production
Activity of recombinant bovine iNOS (155.5 U/ml) was deter-
mined at room temperature in a NOS reaction buffer at pH 7.4
containing 50 mM HEPES, 0.15 mM NADPH, 1 mM arginine, 1 mM
magnesium acetate, 18 mM tetrahydrobiopterin, and 180 mM DTT
in the presence or absence of zinc. The nitrite concentration was
measured in aliquots of the reaction mixture collected at different
time points by chemiluminescence by using triiodide reduction in
CLD 60 (Echophyics GmbH, München, Germany), as described [30].
The results corresponding to 10 min incubations are shown. Nitrite
accumulation in culture supernatants during 24 h of incubation
with pro-inﬂammatory cytokines (as indicated in the ﬁgure
legend) in the absence or presence of the NOS inhibitor L-NIO
was determined using the diazotization reaction (Griess assay), as
described previously [28]. The nitrite concentrations in the cell
culture supernatant were normalized against the number of live
cells as assessed by neutral red staining [13].
Treatments with pro-inﬂammatory cytokines and zinc
Endothelial cells (5104 cells/well) were cultured in 12-well
plates for 48 h and then incubated for 12 h with a mix of pro-
inﬂammatory cytokines (1000 U/ml TNFαþ400 U/ml IL-
1βþ200 U/ml INFγ) to induce the expression of the inducible
nitric oxide synthase (iNOS) and high output NO synthesis. NO
synthesis was inhibited by addition of the speciﬁc NOS-inhibitor L-
NIO (500 mM). Zinc (50 mM stock in 0.9% NaCl) was diluted in
culture medium to the indicated concentrations [12,13].
The effects of iNOS-derived NO7zinc on cell viability was
assessed with three different methods. Cell integrity was assessed
by neutral red staining, as described [12,13]. The amount of cells
accumulating neutral red into their lysosomes (viable cells) is
expressed as percentage of live cells vs. untreated cells. The effects
of the treatments on mitochondrial dehydrogenase activities was
measured by analyzing the reduction of a tetrazolium salt to
formazan [31]. Sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazo-
lium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT;
Roche Diagnostic GmbH, Mannheim, Germany) was used follow-
ing the manufacturer’s instructions. Brieﬂy, 300 ml of a solution
containing XTT was added to the culture medium and incubated
for 4 h at 37 °C, 5% CO2. Absorption was measured in triplicates at
450 nm in a FLUOstar OPTIMA (BMG Labtech, Offenburg, Ger-
many). Cell proliferation was assessed as DNA synthesis by
analyzing the incorporation of 5-bromo-2′-deoxyuridine with a
commercial kit (BrdU Cell Proliferation ELISA, ZytoMed). Brieﬂy,
endothelial cells (104 cells/well) were cultured in 96-well plates
for 24 h, and then treated in quadruplicates as indicated. Six hours
after the beginning of the treatments 20 ml of a solution containing
BrdU (provided in the kit) was added to the culture medium and
incubated for 18 h. Cells were then ﬁxed and stained with an anti-
BrdU mouse monoclonal antibody (1:200) for 1 h at RT. The signal
was detected using a horseradish peroxidase-conjugated goat
anti-mouse antibody (1:2000) and tretra-methylbenzidine as a
substrate. XTT was added to the culture medium and incubated for
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FLUOstar OPTIMA.
RNA interference, RNA extraction and real time RT-PCR
Endothelial cells (1105 cells/well) were grown in a 6-well
plate for 48 h, treated for 24 h as indicated and then lysed with
350 ml RLT-lysis buffer (Qiagen, Hilden, Germany). For gene silen-
cing experiments 105 cells were transfected with 3 nM silencing
RNA (siRNA) and 4.5 ml of HiPerfect transfection reagent (Qiagen)ZnSO4 ( M)
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the culture medium was changed and the cells were treated for
24 h with pro-inﬂammatory cytokines at the concentrations in-
dicated or left untreated. The siRNA sequence targeting RelA (p65)
was purchased from Qiagen (Rn-RelA-2-HPsiRNA). Silencing was
considered successful when RelA (p65) mRNAwas 2-fold decreased
as compared to cells treated with the transfection reagent only
(mock control). The silencing sequence with the maximal efﬁ-
ciency has been selected by comparing silencing efﬁciency, i.e. a
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Fig. 2. Zinc inhibits iNOS expression and activity in endothelial cells. (A) Inhibi-
tion of recombinant iNOS activity as assessed by measuring the accumulation of
nitrite into the reaction buffer after 10 min of incubation with the indicated
concentrations of zinc by reductive chemiluminescence. # T-test po0.05 vs.
control without zinc. (B) Inhibition of cytokine-induced accumulation of nitrite
into the supernatant of endothelial cells by zinc as assessed after 24 h of
incubation. ANOVA po0.001; n po0.05 vs. CTRL (untreated); # po0.05 vs.
Cyt-treated cells. (C) Inhibition of cytokine-induced iNOS protein expression by
zinc as assessed by western blot analysis. Staining of α-tubulin was used as a
loading control.
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reagent only). Other sequences tested and not selected were Rn-
RelA-1-HPsiRNA, Rn-RG2:727889_2_HPsiRNA, and Rn-
RG2:727889_3_HPsiRNA. As a control for unspeciﬁc effects, a
non-silencing (NS) siRNA sequence was used (Qiagen). The posi-
tive control was an siRNA sequence directed against rat Gapdh
mRNA (Dharmacon), which has been used also for determining the
best conditions for transfection. The silencing efﬁciency was
veriﬁed in each experiment by measuring the expression of Gapdh
and RelA (p65) mRNA. RNA was isolated by using RNeasy mini kit
(Qiagen) following the manufacturer’s instruction. The RNA
(0.5 mg) was then reversely transcribed in MyCycler Personal
Thermal Cycler (Bio-Rad Laboratories GmbH, Munich, Germany)
using a QuantiTect Reverse Transcription Kit (Qiagen) following
the manufacturer’s instructions. The cDNA (5 ng) or control RNA
was used as a template for real time PCR performed in triplicate,
using SYBR GreenER™ qPCR SuperMix for ABI PRISMs (Invitrogen,
Karlsruhe, Germany), or TaqMan Universal PCR Master Mix in ABI
PRISM 7900 (Applied Biosystems) and 18 sr RNA as a house-
keeping gene. Primers were purchased from Applied Biosystems:
transporter 1 (Znt1) (NM_022853, assay Rn00575737-m1), and
18S rRNA (Eukaryotic 18S rRNA, endogenous control VIC/TAMRA
primer limited); or from Qiagen: RelA (p65) (QT01580012), in-
ducible NO synthase, nitric oxide type 2 (Nos2) (QT00068740),
interleukin 1beta (il1b) QT00181657 cyclooxygenase 2 (Cox2,
ofﬁcial name: prostaglandin-endoperoxide synthase 2, Ptgs2,
QT00192934), and 18SrRNA (Hs-RRN18S-1-SG). Primer speciﬁcity
was veriﬁed by melting curve analysis. Results were analyzed as
described [13].
Preparation of total and nuclear protein extracts, and western blot
analysis
Total protein lysate was prepared as previously described [12,13]
from endothelial cells grown in a 6-well plate and treated for 24 h
with pro-inﬂammatory cytokines7zinc, as indicated in the ﬁgure
legends. Nuclear protein extracts were obtained from endothelial cells
grown in 100mm dishes (107 cells/plate) for 48 h and then treated for
30 min with pro-inﬂammatory cytokines7zinc as indicated. Nuclei
were extracted with Nuclear extract kit (Active Motif, Carlsbad, USA)
following the manufacturer’s protocol. Protein concentration was
determined by the Lowry assay (DC Protein Assay, Bio-Rad). Total
cell lysates (30 mg) and nuclear cells extracts (10 mg) were denatured
and were loaded together with protein markers (Magic Mark,
Invitrogen) on a 10% NuPAGE Bis-Tris pre-cast gel following the
manufacture’s protocols. The proteins were transferred on PVDF
membrane Hybond P (Amersham Biosciences, GE Healthcare, Frei-
burg, Germany). Staining was performed as described [13] with
mouse anti-NOS2 or mouse anti RelA (p65) antibodies (BD Bios-
ciences, Heidelberg, Germany) diluted 1:1000 or anti-human-actin
(1:5000) and then incubated with HRP-conjugated goat anti-mouse
antibody diluted 1:5000 in blocking buffer. The bands were visualized
by autoradiography on Hyperﬁlm ECL (Amersham Biosciences) using
SuperSignal west Pico Chemiluminescent Substrate (Pierce, Thermo
Lifescience, Bonn, Germany).
Determination NF-κB-dependent gene expression activation and iNOS
promoter activity
To measure the effects of zinc on cytokine-dependent κB
responsive element activation in endothelial cells, endothelial
cells were transfected with a reporter vector pGL4.32[luc2P/NF-
κB-RE/Hygro] with 5 NF-κB responsive elements controlling the
expression of a luciferase (Promega, Mannheim, Germany). En-
dothelial cells (105 cells/well) were seeded on to a 6-well plate
and grown for 48 h, and then transfected with 2 mg plasmid,0.2 mg Renilla luciferase expression vector (pRL3-SV40), and 8 ml
lipofectin (Invitrogen). 24 h after transfection cells were treated
with pro-inﬂammatory cytokines7zinc for 6 h and then lysed in
150 ml of a lysis buffer (reporter gene assay lysis buffer, Roche
Diagnistic GmbH), centrifuged at 13,000g for 2 min at 4 °C in
Universal 30RF (Hettich Zentrifugen), quick frozen in liquid N2,
and stored at 80 °C until luciferase assays was performed.
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Fig 3. Zinc inhibits cytokine-induced expression of pro-inﬂammatory genes. Zinc
supplementation of cytokine-treated cells for 24 h decreased the mRNA levels of
(A) Nos2, (B) IL-1β, (C) Cox2 mRNA as assessed by real time RT-PCR. n po0.05 vs.
Cyt-treated cells.
M.M. Cortese-Krott et al. / Redox Biology 2 (2014) 945–954 949To speciﬁcally determine the effects of zinc on cytokines-
dependent transactivation of the iNOS promoter, A549/8 iNOS
cells were treated for 6 h as indicated and then lysed as described
above.
Luciferase assay was carried out in a luciferase assay buffer
(30 mM tricine, 0.1 mM EDTA, 15 mM MgSO4, 10 mM DTT) sup-
plemented with 0.27 mM coenzyme-A (Applichem, Darmstadt,
Germany), 0.53 mM ATP and with 0.5 mM of the substrate D-
luciferine (Applichem). Cell lysate (20 ml) was assayed in double
for luminescence using a microtiter plate reader with automaticinjection (FLUOstar OPTIMA, BMG). The light units (LU) of the
luciferase assay were normalized by protein content and were
calculated as relative luciferase activity given in percent as
compared to the controls (¼100%).Statistical analysis
Real-time PCR data were processed as described [13]. Data are
reported as mean7SEM. For statistical analysis, we used ANOVA
followed by an appropriate post hoc multiple comparison test
(Tukey or Student’s T test).Results
Zinc reverses iNOS activity-dependent inhibition of endothelial cell
proliferation
We aimed to study whether zinc might affect iNOS activity in
endothelial cells. The expression of iNOS was induced by treating
primary rat aorta endothelial cells with a mixture of pro-inﬂam-
matory cytokines (IL-1βþ INFγþTNFα), which leads to a signiﬁcant
accumulation of nitrite in the supernatant found after 6–8 h of
incubation (Supplementary Fig. S1). Accumulation of nitrite was
fully inhibited by treatment with 500 mM of the speciﬁc NOS
inhibitor L-NIO (Supplementary Fig. S1).
To increase intracellular “free” zinc concentrations, a zinc
solution obtained by dissolving ZnSO4 in NaCl 0.9% was added
directly to the culture medium (containing 2.2870.32 mM zinc).
This treatment induced a concentration-dependent increase in the
intracellular ﬂuorescence intensity of the zinc-speciﬁc ﬂuorophore
Zinquin, which could be observed immediately (o30 s) after
addition of zinc to the medium [13]. Fig. 1A shows the increases
of Zinquin ﬂuorescence before and 5 min after adding 100 mM zinc.
After the addition of 100 mM ZnSO4, intracellular Zinquin ﬂuores-
cence increased approximately 3 folds. As a result of an increase in
“free” bioavailable zinc, the expression of zinc transporter 1 (ZnT-
1) (Fig. 1C) and metallothionein (MT1a) [13] is induced in the
endothelial cells.
The toxicity of the treatment was tested by treating endothelial
cells with different concentrations of ZnSO4 in the absence or in
the presence of cytokines, or the NOS-inhibitor L-NIO (Fig. 1B).
Under the experimental conditions chosen the toxicity of 24 h
incubation with zinc in cytokine-treated cells was not different
from untreated cells (half maximal lethal dose (LD50)¼
547785 mM with zinc vs. LD50¼579791 mM without zinc). To
test the effects of zinc supplementation on metabolic activity and
proliferation of cytokine-treated cells, we measured the mitochon-
drial dehydrogenase catalyzed reduction [31] of XTT into formazan
(Fig. 1D) and the incorporation of BrdU into the DNA (Fig. 1E),
respectively. We found that cytokines increased metabolic activity
of the cells by about 20% (Fig. 1D, Cyt), but decreased cell
proliferation by about 40% (Fig. 1E, Cyt) as compared to untreated
cells (Fig. 1D, E, CTRL). These effects were inhibited by adding the
speciﬁc NOS inhibitor L-NIO (500 mM; Fig. 1D, E, CytþL-NIO),
indicating that NOS-derived NO production is responsible for the
cytokine-induced effects. Addition of non-toxic zinc concentra-
tions to cytokine treated cells exerted the same effects as NOS
inhibition on the effects induced by cytokines on cell proliferation
and mitochondrial dehydrogenase activity, respectively (Fig. 1D, E,
100 mM ZnSO4).
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expression in endothelial cells
Next we aimed to analyze whether zinc might affect iNOS-
dependent NO production in endothelial cells. We found that
concentrations 450 mM zinc affect the catalytic activity of recom-
binant iNOS in vitro, as tested by measuring the accumulation of
nitrite in the reaction buffer by chemiluminescence analysis
(Fig. 2A). In endothelial cells, addition of zinc decreased nitrite
accumulation in the supernatant of cytokine-treated endothelial
cells as measured after 24 h of incubation (Fig. 2B). We found that
zinc added together with cytokines shown in Fig. 2B, or 6 h after
the treatment with cytokines (not shown) strongly decreased iNOS
expression as shown by Western blotting (Fig. 2C).
Zinc inhibits iNOS expression by affecting NF-κB-dependent gene
transcription
To verify whether these effects were mainly dependent on
zinc-mediated inhibition of iNOS transcription, iNos (Nos2) mRNA
levels were measured by real-time RT-PCR. Cytokines increased
the levels of Nos2 mRNA already after 2–4 h of incubation (not
shown), reaching the maximum after 6–8 h (Fig. 3A shows the
results after 6 hours of incubation). In the presence of zinc, Nos2
mRNA levels strongly decreased. Similarly, the expression of two
NF-κB-dependent inﬂammatory genes Cox2 (Fig. 3B) and IL-1β
(Fig. 3C) was strongly affected by zinc, as assessed after 6 h of
incubation. Interestingly, inhibition of iNOS during cytokines
exposure results in about the same effect on mRNA for iNOS,
COX2, IL-1β as zinc exposure.
Next, we studied whether NF-κB was involved in zinc-mediated
inhibition of iNOS expression. We knocked down the expression of
the NF-κB (p50/p65) by transfecting endothelial cells with an
siRNA directed against p65, which decreased mRNA levels of p65
to a minimum of 90%. Cytokine-induced iNOS expression in theabsence of NF-κB was decreased by almost 99% (Fig. 4A), conﬁrm-
ing that NF-κB is the dominant transcription factor involved in
cytokine-induced iNOS expression in our cells. To analyze whether
zinc affects NF-κB translocation into the nucleus, the presence of
p65 in the cytoplasmic as well as the in the nuclear fraction of
endothelial cells was assessed by western blot analysis (Fig. 4B).
Treatment with zinc did not affect the cytokine-induced translo-
cation of p65 into the nucleus. In fact, the amount of p65 found in
the nucleus of cytokine-treated cells after a 1 h-incubation with
cytokinesþzinc is not different as found in cells treated with
cytokines only (Fig. 4B).
We further found that treatment with zinc decreased cytokine-
induced transcriptional activation of an NF-κB-reporter plasmid,
which was transiently transfected in the endothelial cells (Fig. 4C).
To further conﬁrm that zinc inhibits transactivation of iNOS
promoter, we repeated these experiments by using a reporter cell
line transfected with 1.3 kB of a human iNOS promoter in front of a
luciferase reporter gene. We found that zinc decreased the
cytokine-induced luciferase activity also in this cell line (Fig. 4D).
Zinc itself did not affect luciferase basal activity or the viability of
A549 cells as tested by neutral red assay (not shown).
Taken together these data show that zinc inhibits iNOS expres-
sion and activity via inhibition NF-κB-dependent transactivation of
the iNOS promoter.Discussion
In this study we found that an increase in intracellular “free”
zinc concentration by addition of exogenous zinc results in a
decreased NF-κB-dependent activation of iNOS expression in
endothelial cells, thereby limiting high output NO production
and cell activation, while promoting cell proliferation under pro-
inﬂammatory conditions. Thus we found that 1. addition of non-
toxic zinc concentrations to cultured primary endothelial cells
p65 
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Fig. 5. Potential feedback regulation of iNOS expression by zinc in endothelial cells.
Pro-inﬂammatory cytokines induce iNOS expression. iNOS-derived NO induces zinc
release from zinc clusters of intracellular proteins. We here show that zinc
decreases NF-κB mediated iNOS expression.
M.M. Cortese-Krott et al. / Redox Biology 2 (2014) 945–954 951increased intracellular “free” zinc concentrations as demonstrated
by increased Zinquin ﬂuorescence, and increases in mRNA levels of
the zinc responsive gene Znt1, 2. similar to NOS inhibition, zinc
reverses cytokine-dependent inhibition of endothelial cell prolif-
eration, 3. zinc decreases cytokines-induced iNOS expression and
high out NO synthesis, and 4. zinc decreases NF-κB-mediated
transactivation of iNOS promoter. Taken together these results
show that zinc limits iNOS-derived high-output NO production in
endothelial cells by inhibiting NF-κB-mediated transactivation of
iNOS promoter, pointing to a role of zinc as a regulator of iNOS
activation in inﬂammation in endothelial cells.
Zinc-mediated inhibition of iNOS activity
Although in recent years both post-transcriptional as well as
post-translational mechanisms regulating iNOS activity have been
discovered [4], the regulation of iNOS expression remains the main
regulatory step to control iNOS activity. Usually iNOS synthesizes
NO continuously until the enzyme becomes degraded. We here
found that zinc strongly decreases cytokine-induced iNOS expres-
sion (mRNAþprotein) as well as NOS-dependent nitrite accumu-
lation in the culture medium of the endothelial cells. Similar
results were previously obtained with mouse keratinocytes [27],
but the molecular mechanisms involved were not further investi-
gated. As shown here, zinc directly inhibits iNOS catalytic activity
in a concentration-dependent fashion (EC50E75 mM), but would
require local intracellular zinc concentrations of 450 mM. The
inhibitory effects exerted by zinc on NOS catalytic activity are well
known [25,26], and other divalent transition metals like copper
exert similar effects at micromolar concentrations. Total cellular
zinc concentrations are in the range of a few hundred micromolar,
and it is distributed within sub-cellular compartments. However,
the afﬁnity of zinc for cytosolic zinc proteins is in the picomolar
range, suggesting that the availability of free zinc ions within the
cytoplasm is quite low [11]. In lysosomes and zincosomes the
concentration of zinc may reach millimolar concentrations. Since
iNOS is mainly localized within the cytoplasmic compartment of
the cell, we may exclude a direct effect of zinc ions on the enzyme
itself. Therefore, we conclude that the effects of zinc supplementa-
tion on iNOS activity within the endothelial cells are mainly
dependent on the modulation of iNOS expression.
By using a reporter cell line stably transfected with the human
iNOS promoter, we found that zinc supplementation directly
inhibits the cytokine-mediated activation of the iNOS promoter.
The sequence of human, rat and mouse iNOS promoters show ahigh grade of homology. The transcription factor NF-κB seems to
be a central target for activators or inhibitors of iNOS expression in
all three species. Pro-inﬂammatory stimuli including LPS, IL-1β,
TNFα, in combination with INFγ, have been shown to induce iNOS
expression in different cell types via activation of NF-κB [4]. By
silencing the expression of p65, we found a 99% reduction of
cytokine-induced up-regulation of iNOS, conﬁrming that in our
system NF-κB plays a central role in cytokine-mediated induction
of iNOS expression. The rat promoter contains an upstream (965
to 956 bp) and downstream (107 to 98) NF-κB site, both of
which are important for iNOS induction. In the rat promoter a
third NF-κB site located at 901 to 892 bp with an opposite
orientation, also deﬁned as “the reverse NF-κB site”, is important
for IL-1β-/INFγ-induced promoter activity [32].
We here show that zinc-mediated down regulation of iNOS
expression is due to inhibition of NF-κB transactivation activity,
and not NF-κB activation/translocation into the nucleus. The active
transcription factor, which typically is the p50/p65 heterodimer
[33], is released from an inhibitory cytosolic complex and translo-
cates into the nucleus to bind to κB-responsive elements upstream
of its target genes. Inhibition of NF-κB can occur by direct capture
of NF-κB via protein–protein interactions [34], inhibition of NF-κB
phosphorylation [35], inhibition of nuclear NF-κB-translocation
[36], inhibition of NF-κB transactivation activity [37], or by
increasing the expression of i-κB, the speciﬁc inhibitor of NF-κB
[38].
We found that zinc inhibited NF-κB transactivation activity in
cytokine-treated endothelial cells, as assessed by transient trans-
fection of a κB-luciferase construct. While inhibition of the NF-κB
signaling by zinc was shown in different tissues and cells, the
mechanisms involved are cell/tissue speciﬁc and unknown for
many cell types [39,40]. Zinc was shown to inhibit NF-κB activa-
tion/translocation in mononuclear cells [35,41], and other cell
types [35,42,43] and to reduce the levels of activated NF-κB in
diabetic CD1 mice [44], Severe zinc deﬁciency was shown to
inhibit the translocation and transactivation capacity of NF-κB in
neuronal cells and rat testes [45,46]. Zinc chelation has been
shown to increase LPS-induced iNOS expression in RAW 264.7
cells [47]. In endothelial cells it was shown that zinc affects the
expression of pro-inﬂammatory cytokines [48,49], while zinc
deﬁciency exerts a permissive effect on the expression of inﬂam-
matory genes and exacerbates chronic inﬂammation in endothelial
cells [48,49]. However, to the best of our knowledge this is the ﬁrst
time that zinc was shown to regulate iNOS expression via inhibi-
tion of NF-κB transactivation in primary endothelial cells. Future
studies should be undertaken to investigate the molecular me-
chanisms responsible for zinc-mediated inhibition of transactiva-
tion activity of NF-κB into the nucleus.
Zinc and cell signaling: in vitro evidence and limitations
Because zinc ion ﬂuctuations occur at such low concentrations
and zinc interacts strongly with proteins, released zinc ions are
now considered as potent intracellular signals [9,11]. Picomolar to
low nanomolar concentrations of zinc ions inhibit enzymes
involved in energy metabolism, signaling and mitochondrial
respiration [50–54]. Here we found that zinc ion ﬂuctuation in
cytokine-treated cells induced by administration of non-toxic zinc
concentrations, reduced the activation of the cells [55] and
rescued their proliferation capability, leading to inhibition of iNOS
expression and activity. Changes in intracellular free zinc concen-
trations and zinc ion ﬂuctuations were induced here by exogenous
administration of zinc ions to the culture medium, as demon-
strated by analyzing increases in intracellular Zinquin ﬂuores-
cence, and in the expression of zinc-responsive genes, including
metallothionein-1 (MT-1) and zinc transporter-1 (ZnT1) [13,16].
M.M. Cortese-Krott et al. / Redox Biology 2 (2014) 945–954952Metallothioneins and zinc transporters contribute to rapidly “buf-
fer” high intracellular zinc concentrations either by binding zinc
(e.g. MT-1), or by transporting zinc outside of the cell (e.g. ZnT1) or
into sub-cellular compartments, like lysosomes and zincosomes
(e.g. via ZnT2 and/or other zinc transporters) [56], which also
explains why cells are resistant to micromolar levels of zinc.
Should we consider the changes of intracellular “free” zinc,
which are induced by adding micromolar concentrations of zinc to
the culture media, physiological or superphysiological? Are the
responses to these zinc ﬂuctuations relevant for in vivo biology
and/or pharmacology of zinc? The concentrations of zinc needed
to increase the intracellular zinc concentrations in our endothelial
culture system [12,13] are 5–20 fold higher as the zinc concentra-
tions found in serum of healthy persons (about 12–15 mmol/l; 78–
98 mg/dl) [57]. The effects of zinc supplementation to cultured
cells are strongly dependent on the cell type under consideration,
but also on the composition of the cell culture media, which may
contain micromolar levels of zinc and millimolar concentrations of
zinc-complexing molecules/chelators [58]. In our medium, we
measured a total zinc concentrations of 2.2870.32 mM, as as-
sessed in 3 different media preparations. As pointed out by Bozym
et al. [58], in media containing 5–10% v/v serum, albumin is
present at a concentration of 0.3 mmol/l, and therefore will bind
a signiﬁcant portion of the available zinc with relatively high
afﬁnity (KD¼0.1 mmol/l). The “free” zinc concentration is typically
two to three orders of magnitude below the total added zinc, such
that adding 100 mmol/l total zinc typically resulted in
100 nmol/l free zinc (pZn¼7) being present, as assessed by
different ﬂuorimetric methods [58]. This means that in serum
containing media the zinc levels are functionally buffered [58].
This is very similar to the in vivo situation were zinc is transported
in the serum bound principally to albumin (70%), α-2-macroglo-
bulin (18%), and other proteins such as transferrin or ceruloplas-
min. A very small amount (i.e., 0.01%) is complexed with amino
acids, especially histidine and cysteine [57,58]. As also pointed out
by Bozym et al., care is particularly necessary if cells are cultured
in serum-free media, since zinc buffering ligands may be inade-
quate. The same could be said if zinc chelators – like pyrithione –
is used to transport zinc inside the cells. Both zinc-depleted media
or chelators decrease the effective dosis of zinc used for experi-
ments, but may also interfere with intracellular zinc equilibrium
and with zinc signaling. The equilibrium between buffering and
ﬂuctuation of zinc ions will determine the borderline between
physiology and pathophysiology [11].
Although we carefully characterized our model for: 1. concen-
tration of zinc in media and sera; 2. increases in intracellular “free”
zinc concentrations; 3 bioactivity of zinc, as shown by increases in
the expression of the zinc responsive gene Znt1; 3. lack of overall
toxicity, metabolic activity or proliferation, we cannot provide
direct evidence that the effects exerted by zinc in vitro in this and
other similar studies are also relevant for in vivo biology. This is
one of the main limitations of cell culture models. The role of zinc
in iNOS regulation in the endothelium should be addressed in
future study in animal models, and in humans.
Are iNOS and zinc signaling pathways interdependent?
We and others have shown that iNOS-derived NO can nitrosate
metallothionein [59] and thereby induce zinc release. Zinc re-
leased by NO may exert signaling functions leading to both
cytoprotection as shown in endothelial cells by us [12,14] or in
the lung [17,19], as well as to neurotoxicity in the brain [60],
depending on the cellular compartment. By considering zinc-
mediated inhibition of iNOS, it is tempting to speculate that zinc
released by iNOS-derived NO may be part of the termination
signals needed for the control of acute inﬂammatory reactions.Thus, under pro-inﬂammatory conditions, NF-κB activation leads
to endothelial cell activation corresponding to the expression of
inﬂammatory genes, including pro-inﬂammatory cytokines and
iNOS, and contribute to the propagation of the inﬂammatory
response. In activated endothelial cells expression of iNOS is
induced and long-term high-output NO synthesis follows. iNOS-
derived NO may then induce zinc release from zinc–sulfur clusters
of intracellular proteins, and NF-κB might be a target of NO-
mediated zinc redistribution [40,61]. If this would be the case, the
NO-mediated intracellular zinc release may contribute to limit an
excessive propagation of the inﬂammatory response by inhibiting
or limiting endothelial cell activation. At present, this feedback
loop connecting iNOS-mediated zinc release, and zinc mediated
inhibition of iNOS expression should be considered a speculative
observation, which should be addressed experimentally in future.
Summary and conclusions
To summarize, we here have shown that zinc ions control iNOS
expression and activity in endothelial cells via inhibition of NF-κB
transactivation activity (Fig. 5). Interestingly, it has been shown
that not only zinc supplementation inhibits NF-κB activation, but
also that zinc deﬁciency exerts a permissive effect on the expres-
sion of inﬂammatory genes and exacerbates chronic inﬂammation
[48,49]. Therefore, zinc signals and the maintenance of an ade-
quate zinc status in the endothelium may be an important clinical
strategy to prevent the development of endothelial dysfunction
and cardiovascular diseases.Acknowledgements
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